vs
Amphastar Pharmaceuticals, Inc.(AMPH)とAPPFOLIO INC(APPF)の財務データ比較。上の社名をクリックして会社を切り替えられます
APPFOLIO INCの直近四半期売上が大きい($262.2M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.4倍)。APPFOLIO INCの純利益率が高く(16.2% vs 13.3%、差は2.8%)。APPFOLIO INCの前年同期比売上増加率が高い(20.4% vs -1.8%)。過去8四半期でAPPFOLIO INCの売上複合成長率が高い(15.3% vs 3.2%)
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
AppFolio Inc.は2006年に設立された米国の企業で、不動産業界を対象にSaaS(ソフトウェア・アズ・ア・サービス)のアプリケーションや各種サービスを提供し、不動産関連企業の業務効率向上と管理プロセスの最適化をサポートしています。
AMPH vs APPF — 直接比較
売上が大きい
APPF
1.4倍大きい
$183.1M
売上成長率が高い
APPF
+22.3%の差
-1.8%
純利益率が高い
APPF
純利益率が2.8%高い
13.3%
2年売上CAGRが高い
APPF
2年複合成長率
3.2%
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | ||
|---|---|---|
| 売上 | $183.1M | $262.2M |
| 純利益 | $24.4M | $42.4M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 19.4% |
| 純利益率 | 13.3% | 16.2% |
| 売上前年比 | -1.8% | 20.4% |
| 純利益前年比 | -35.7% | 35.2% |
| EPS(希薄化後) | $0.51 | $1.18 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上
AMPH
APPF
| Q1 26 | — | $262.2M | ||
| Q4 25 | $183.1M | $248.2M | ||
| Q3 25 | $191.8M | $249.4M | ||
| Q2 25 | $174.4M | $235.6M | ||
| Q1 25 | $170.5M | $217.7M | ||
| Q4 24 | $186.5M | $203.7M | ||
| Q3 24 | $191.2M | $205.7M | ||
| Q2 24 | $182.4M | $197.4M |
純利益
AMPH
APPF
| Q1 26 | — | $42.4M | ||
| Q4 25 | $24.4M | $39.9M | ||
| Q3 25 | $17.4M | $33.6M | ||
| Q2 25 | $31.0M | $36.0M | ||
| Q1 25 | $25.3M | $31.4M | ||
| Q4 24 | $38.0M | $102.7M | ||
| Q3 24 | $40.4M | $33.0M | ||
| Q2 24 | $37.9M | $29.7M |
粗利率
AMPH
APPF
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
営業利益率
AMPH
APPF
| Q1 26 | — | 19.4% | ||
| Q4 25 | 19.4% | 17.6% | ||
| Q3 25 | 13.2% | 14.1% | ||
| Q2 25 | 24.2% | 17.2% | ||
| Q1 25 | 21.9% | 15.5% | ||
| Q4 24 | 24.2% | 11.3% | ||
| Q3 24 | 29.8% | 20.7% | ||
| Q2 24 | 30.3% | 18.3% |
純利益率
AMPH
APPF
| Q1 26 | — | 16.2% | ||
| Q4 25 | 13.3% | 16.1% | ||
| Q3 25 | 9.0% | 13.5% | ||
| Q2 25 | 17.8% | 15.3% | ||
| Q1 25 | 14.8% | 14.4% | ||
| Q4 24 | 20.4% | 50.4% | ||
| Q3 24 | 21.1% | 16.0% | ||
| Q2 24 | 20.8% | 15.0% |
EPS(希薄化後)
AMPH
APPF
| Q1 26 | — | $1.18 | ||
| Q4 25 | $0.51 | $1.10 | ||
| Q3 25 | $0.37 | $0.93 | ||
| Q2 25 | $0.64 | $0.99 | ||
| Q1 25 | $0.51 | $0.86 | ||
| Q4 24 | $0.74 | $2.79 | ||
| Q3 24 | $0.78 | $0.90 | ||
| Q2 24 | $0.73 | $0.81 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $147.4M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $470.2M |
| 総資産 | $1.6B | $580.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資
AMPH
APPF
| Q1 26 | — | $147.4M | ||
| Q4 25 | $282.8M | $107.0M | ||
| Q3 25 | $276.2M | $76.1M | ||
| Q2 25 | $231.8M | $73.5M | ||
| Q1 25 | $236.9M | $56.9M | ||
| Q4 24 | $221.6M | $42.5M | ||
| Q3 24 | $250.5M | $62.4M | ||
| Q2 24 | $217.8M | $59.6M |
総負債
AMPH
APPF
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
株主資本
AMPH
APPF
| Q1 26 | — | $470.2M | ||
| Q4 25 | $788.8M | $542.6M | ||
| Q3 25 | $776.7M | $498.9M | ||
| Q2 25 | $757.5M | $455.6M | ||
| Q1 25 | $751.3M | $462.1M | ||
| Q4 24 | $732.3M | $519.3M | ||
| Q3 24 | $727.7M | $412.8M | ||
| Q2 24 | $713.3M | $371.4M |
総資産
AMPH
APPF
| Q1 26 | — | $580.6M | ||
| Q4 25 | $1.6B | $689.0M | ||
| Q3 25 | $1.7B | $640.5M | ||
| Q2 25 | $1.6B | $567.4M | ||
| Q1 25 | $1.6B | $564.7M | ||
| Q4 24 | $1.6B | $626.7M | ||
| Q3 24 | $1.5B | $523.3M | ||
| Q2 24 | $1.5B | $479.3M |
負債/資本比率
AMPH
APPF
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $34.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 0.81× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフロー
AMPH
APPF
| Q1 26 | — | $34.3M | ||
| Q4 25 | $32.9M | $65.0M | ||
| Q3 25 | $52.6M | $86.0M | ||
| Q2 25 | $35.6M | $52.6M | ||
| Q1 25 | $35.1M | $38.5M | ||
| Q4 24 | $29.0M | $36.6M | ||
| Q3 24 | $60.0M | $57.8M | ||
| Q2 24 | $69.1M | $50.9M |
フリーキャッシュフロー
AMPH
APPF
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $63.7M | ||
| Q3 25 | $47.2M | $84.7M | ||
| Q2 25 | $25.0M | $52.4M | ||
| Q1 25 | $24.4M | $38.2M | ||
| Q4 24 | $16.6M | $36.4M | ||
| Q3 24 | $46.2M | $57.4M | ||
| Q2 24 | $63.1M | $50.8M |
FCFマージン
AMPH
APPF
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 25.7% | ||
| Q3 25 | 24.6% | 34.0% | ||
| Q2 25 | 14.3% | 22.2% | ||
| Q1 25 | 14.3% | 17.6% | ||
| Q4 24 | 8.9% | 17.9% | ||
| Q3 24 | 24.1% | 27.9% | ||
| Q2 24 | 34.6% | 25.8% |
設備投資強度
AMPH
APPF
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.5% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 6.7% | 0.1% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 3.3% | 0.0% |
キャッシュ転換率
AMPH
APPF
| Q1 26 | — | 0.81× | ||
| Q4 25 | 1.35× | 1.63× | ||
| Q3 25 | 3.03× | 2.56× | ||
| Q2 25 | 1.15× | 1.46× | ||
| Q1 25 | 1.39× | 1.23× | ||
| Q4 24 | 0.76× | 0.36× | ||
| Q3 24 | 1.48× | 1.75× | ||
| Q2 24 | 1.82× | 1.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APPF
| Value Added Services | $201.4M | 77% |
| Subscription Services | $58.2M | 22% |